Is Poxel SA halal to invest in?

According to Musaffa's Shariah screening methodology, Poxel SA (POXEL.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Poxel SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Poxel SA using these criteria to determine its compliance status.

Can Muslims buy shares of Poxel SA?

Muslim investors may consider investing in Poxel SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Poxel SA classified as NOT HALAL?

Musaffa determines the Shariah status of Poxel SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Poxel SA updated?

The Shariah compliance status of Poxel SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Poxel SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Poxel SA?

You can check the latest Shariah compliance status of Poxel SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Poxel SA POXEL.PA

€0.25 €0.00 (0.98%) 1D

Last Updated: May 15, 12:00 AM·XPAR

POXEL.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 25, 2025

Report Source: 2024 2nd Quarter Report

Analyst's Ratings for Poxel SA (POXEL.PA)

Based on 9 analysts giving stock ratings to Poxel SA in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Poxel SA. Stock Analysis POXEL.PA

France Health Care Nano Cap Report: Q2, 2024

Poxel SA is a clinical-stage biopharmaceutical company, which engages in the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). The firm develops drugs with a focus on Type 2 diabetes. The firm aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The firm cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.

Key Statistics of Poxel SA (POXEL.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.25€0.26

Today's Open

€0.26

Volume

183.70K

P/E Ratio (TTM)

52 Week Range

€0.22€0.83

Market Cap

13.48M

Avg. Volume

95.31K

Dividend Yield

Financial Metrics & Statements of Poxel SA (POXEL.PA)

FAQ's for Poxel SA (POXEL.PA)

According to Musaffa’s Shariah screening methodology, Poxel SA (POXEL.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.